Add BrightSurf on Google Email

Boston Children's Hospital


A new target for lymphoma therapy

Researchers at Boston Children's Hospital have discovered a gene enhancer responsible for activating cancer-causing genes in B cells, leading to the development of a new target for lymphoma therapy. The study suggests that targeting this regulatory component could potentially arrest lymphomas and other blood-related cancers.

SourceBoston Children's Hospital·JournalNature·DateDec 9, 2009

When should flu trigger a school shutdown?

A study by Boston Children's Hospital researchers suggests three optimal scenarios for school closures: single-day absentee rate of 5%, consecutive days of 4% or more absenteeism, and three consecutive days of 3% or more. Scenario #2 is preferred for its balance between sensitivity and specificity.

SourceBoston Children's Hospital·JournalEmerging Infectious Diseases·DateNov 4, 2009

Understanding the implications of prenatal testing for Down syndrome

The introduction of new prenatal tests for Down syndrome has led to a steady decrease in births of babies with the condition since their introduction. Experts argue that existing tests may not be providing accurate information, leading to difficult conversations between physicians and expectant parents. To address this, researchers are...

SourceBoston Children's Hospital·JournalArchives of Disease in Childhood·DateSep 14, 2009

Injection reverses heart-attack damage

A growth factor called neuregulin1 can spur heart-muscle growth and recovery of cardiac function when injected systemically into animals after a heart attack. Researchers were able to restart the cell cycle with NRG1, stimulating cardiomyocytes to divide and make copies of themselves - even though they are not stem cells.

A drug-dispensing contact lens

Researchers at Boston Children's Hospital have developed a drug-dispensing contact lens that can gradually release medication to the eye. The prototype lens dispensed antibiotic ciprofloxacin for up to 30 days in laboratory testing, with potential applications in conditions like glaucoma and dry-eye.

SourceBoston Children's Hospital·JournalInvestigative Ophthalmology & Visual Science·DateJul 21, 2009

A urine test for appendicitis?

Researchers at Boston Children's Hospital developed a protein detectable in urine as a potential biomarker for appendicitis. The leucine-rich alpha-2-glycoprotein (LRG) marker showed near-perfect sensitivity and specificity, and was strongly elevated in diseased appendices.

SourceBoston Children's Hospital·JournalAnnals of Emergency Medicine·DateJun 23, 2009

A new lead for autoimmune disease

Researchers discover halofuginone, a compound from traditional Chinese medicine, inhibits Th17 cells and reduces disease pathology in mouse model of autoimmunity. Halofuginone may offer a new treatment option for autoimmune disorders with potential for oral administration.

SourceBoston Children's Hospital·JournalScience·DateJun 4, 2009

New study evaluates community response to personally controlled health information

A new study evaluated the community's response to Indivo, a personalized health record system. The two-year study found that issues such as health literacy, accessibility, and privacy were relevant factors in PCHR adoption. Researchers advocate for continued evaluation of PCHRs and discussions on technical and policy approaches to adva...

SourceBoston Children's Hospital·JournalJournal of Medical Internet Research·DateMay 1, 2009

A glimpse at vision: First impressions count

Researchers at Children's Hospital Boston demonstrate that the brain can recognize objects quickly and consistently, even under different lighting conditions, size, and rotation. This finding could lead to advancements in teaching computers to see and improving brain-computer interfaces for individuals with visual impairment.

SourceBoston Children's Hospital·JournalNeuron·DateApr 29, 2009

Long-lasting nerve block could change pain management

Researchers at Boston Children's Hospital have created a slow-release anesthetic drug-delivery system, showing promise for prolonged pain relief without toxicity in rats. The formulation, using liposomes to package saxitoxin, produced nerve blocks lasting two days or seven days when combined with dexamethasone.

SourceBoston Children's Hospital·JournalProceedings of the National Academy of Sciences·DateApr 15, 2009

Low-income families with sick children often enrolled in high-deductible health care plans

A study from Boston Children's Hospital and Harvard Medical School found that low-income families with children who have chronic conditions are more likely to be enrolled in high-deductible health plans. The study analyzed data from 839 families who were switched from traditional plans to high-deductible plans, revealing a higher perce...

SourceBoston Children's Hospital·JournalPEDIATRICS·DateMar 30, 2009

Billions spent on health IT stimulus could lead to major boom... or bust

Researchers propose a platform model for health information infrastructure that would improve healthcare delivery, increase productivity and stimulate job growth. The model aims to support applications for clinical care, public health, and research, with key characteristics including data liquidity and substitutability of applications.

SourceBoston Children's Hospital·JournalNew England Journal of Medicine·DateMar 25, 2009

A fast magnetic fix for sepsis?

A team of researchers has created a microdevice that uses magnetism to remove pathogens from the bloodstream, showing promise as a potential treatment for sepsis. The device, developed by Chong Wing Yung and Don Ingber, achieved over 80% clearance of fungi in contaminated human blood.

SourceBoston Children's Hospital·JournalLab on a Chip·DateMar 25, 2009

Metastasis-promoting protein identified; could provide a prognostic test or target for breast cancer

A study by Boston Children's Hospital researchers has identified lipocalin 2 as a protein that triggers the epithelial to mesenchymal transition in human breast cancer cells, increasing invasiveness and metastasis. The protein is detectable in urine samples, suggesting it may be used for prognostic testing.

SourceBoston Children's Hospital·JournalProceedings of the National Academy of Sciences·DateFeb 23, 2009

Balancing the brain

Neuroscientists identified Npas4 as the first known master switch to orchestrate inhibitory synapse formation and maintenance. This factor regulates over 200 genes involved in calming down over-excited cells, restoring balance that's thought to go awry in neurologic disorders.

SourceBoston Children's Hospital·JournalNature·DateSep 24, 2008

Trigger for brain plasticity identified

Scientists at Boston Children's Hospital have identified the Otx2 protein as a key factor in triggering brain plasticity, allowing the brain to rewire and adapt. This discovery has implications for understanding developmental disorders like autism and potential treatments for improving learning and cognitive function.

SourceBoston Children's Hospital·JournalCell·DateAug 7, 2008